Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience.
作者信息
Kacarska-Fotevska Isidora, Volckova Nadja, Ilievska Katerina, Donev Doncho
机构信息
Doncho Donev, Institute of Social Medicine, Faculty of Medicine, Skopje, North Macedonia,
出版信息
Croat Med J. 2019 Oct 31;60(5):475-478. doi: 10.3325/cmj.2019.60.475.
Abstract
摘要
相似文献
1
Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience.关于确认甲氧基聚乙二醇 - 促红细胞生成素β在血液透析患者贫血治疗中的安全性和有效性：马其顿的经验。
Croat Med J. 2019 Oct 31;60(5):475-478. doi: 10.3325/cmj.2019.60.475.
2
Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience.甲氧基聚乙二醇-促红细胞生成素β在血液透析患者贫血治疗中的安全性和疗效：马其顿经验。
Med Arch. 2020 Apr;74(2):109-114. doi: 10.5455/medarh.2020.74.109-114.
3
Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.C.E.R.A. 在儿科血液透析伴慢性肾脏病贫血患者中的维持治疗的疗效和长期安全性。
Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2.
4
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.CKD 贫血患者中甲氧基聚乙二醇-促红细胞生成素β与其他促红细胞生成刺激剂的心血管安全性和全因死亡率：一项随机非劣效性试验。
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1701-1710. doi: 10.2215/CJN.01380219. Epub 2019 Aug 16.
5
Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).静脉注射甲氧基聚乙二醇 - 促红细胞生成素β用于控制接受透析的慢性肾病患者的血红蛋白：一项随机非劣效性试验（MAXIMA）
Lancet. 2007 Oct 20;370(9596):1415-21. doi: 10.1016/S0140-6736(07)61599-2.
6
[Methoxy polyethylene glycol epoetin beta].
Rev Infirm. 2010 Apr(159):47-9.
7
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.促红细胞生成素用于治疗成人慢性肾脏病贫血：一项网状Meta分析
Cochrane Database Syst Rev. 2014 Dec 8;2014(12):CD010590. doi: 10.1002/14651858.CD010590.pub2.
8
Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial.波兰日常临床实践中使用持续红细胞生成素受体激活剂治疗慢性透析肾性贫血患者的非干预性、多中心、实用 NAVIGO 试验。
Nephron. 2024;148(2):104-112. doi: 10.1159/000534070. Epub 2023 Sep 14.
9
Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.甲氧基聚乙二醇-促红细胞生成素β作为一种新型促红细胞生成刺激剂，对非透析慢性肾脏病患者可能具有肾脏保护和心血管保护作用。
Curr Pharm Biotechnol. 2017;18(4):303-308. doi: 10.2174/1389201018666170127104801.
10
Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.甲氧基聚乙二醇-β-促红细胞生成素：用于治疗慢性肾脏病相关性贫血的综述
Drugs. 2008;68(8):1139-56. doi: 10.2165/00003495-200868080-00009.
引用本文的文献
1
An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients.缺氧诱导因子脯氨酰羟化酶抑制剂与促红细胞生成素刺激剂在治疗慢性肾脏病患者贫血方面的安全性和有效性概述
Cureus. 2023 Jul 17;15(7):e42045. doi: 10.7759/cureus.42045. eCollection 2023 Jul.
2
Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience.甲氧基聚乙二醇-促红细胞生成素β在血液透析患者贫血治疗中的安全性和疗效：马其顿经验。
Med Arch. 2020 Apr;74(2):109-114. doi: 10.5455/medarh.2020.74.109-114.
本文引用的文献
1
Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience.一组血液透析患者慢性肾脏病相关性贫血的治疗趋势：爱尔兰的经验
Ir J Med Sci. 2019 Feb;188(1):223-230. doi: 10.1007/s11845-018-1823-0. Epub 2018 Apr 27.
2
Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease.肾脏协会慢性肾脏病贫血临床实践指南。
BMC Nephrol. 2017 Nov 30;18(1):345. doi: 10.1186/s12882-017-0688-1.
3
4
Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis.在常规临床实践中使用 C.E.R.A. 治疗贫血：OCEANE（Mircera 患者非透析队列），一项全国性、多中心、纵向、观察性前瞻性研究，纳入未接受透析的慢性肾脏病患者。
BMJ Open. 2013 Mar 9;3(3):e001888. doi: 10.1136/bmjopen-2012-001888.
5
Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease.甲氧基聚乙二醇-β-促红细胞生成素用于治疗慢性肾病所致贫血
Int J Nephrol Renovasc Dis. 2012;5:53-60. doi: 10.2147/IJNRD.S23447. Epub 2012 Mar 30.
6
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.针对红细胞生成刺激剂的目标血红蛋白：在 Aranesp 治疗降低心血管事件试验（TREAT）研究发表后，ERBP 的立场声明。
Nephrol Dial Transplant. 2010 Sep;25(9):2846-50. doi: 10.1093/ndt/gfq336. Epub 2010 Jun 29.
7
Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO).慢性肾脏病贫血临床实践指南：问题与解决方案。来自改善全球肾脏病预后组织（KDIGO）的立场声明。
Kidney Int. 2008 Nov;74(10):1237-40. doi: 10.1038/ki.2008.299. Epub 2008 Jul 2.
8
Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.甲氧基聚乙二醇-β-促红细胞生成素：用于治疗慢性肾脏病相关性贫血的综述
Drugs. 2008;68(8):1139-56. doi: 10.2165/00003495-200868080-00009.
9
The MAXIMA trial.MAXIMA试验。
Lancet. 2008 Jan 26;371(9609):299-300; author reply 300. doi: 10.1016/S0140-6736(08)60160-9.
10
C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.C.E.R.A.纠正未接受透析的慢性肾病患者的贫血：一项随机临床试验的结果。
Clin J Am Soc Nephrol. 2008 Mar;3(2):337-47. doi: 10.2215/CJN.00480107. Epub 2008 Feb 20.
Zotero 插件